PROSpect's phase 3 RCT enrolled 424 children with PARDS and found neither prone positioning nor HFOV improves ventilator-free ...

CluePoints positions RBQM architecture as the structural foundation for clinical monitoring, consolidating evidence across ...

The PROSpect trial found neither prone positioning nor HFOV improved ventilator-free days in PARDS, and the trial design that ...

PharPoint Research joins Medrio's Early Adopter Program to shape clinical trial management system design before product ...

Moleculin Biotech completes dosing in Phase 2/3 MIRACLE trial for AnnAraC in relapsed/refractory AML, with full data expected ...

Zhimeng Biopharma completes enrollment of CB03-154 Phase 2/3 ALS trial with 255 patients across China, targeting Q3 2027 ...

PharPoint Research shaped Medrio CTMS design through early adopter program, influencing clinical trial monitoring workflows ...

Enanta dosed its first RESOLVE patient Oct 26. High-risk adult RSV outpatient capacity is already strained, here's what site ...

Hengrui Pharma presents 64 studies at ESMO 2026, a record for the Chinese oncology company showcasing 14 approved innovative ...

Atrium Therapeutics doses first patient in ATR-1072 trial for PRKAG2 syndrome, targeting the genetic cause of cardiac disease ...

Zemprocitinib maintains ACR20 response in 90% of RA patients at 76 weeks in Phase III trial, with consistent safety profile and comparable crossover rates.

Qutenza meets primary pain endpoint in post-surgical neuropathy trial, showing sustained benefit over ten months in extension ...